Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Kivelae 2014 EMBO Mol Med"

From Bioblast
 
Line 2: Line 2:
|title=KivelÀ R, Bry M, Robciuc MR, RÀsÀnen M, Taavitsainen M, Silvola JM, Saraste A, Hulmi JJ, Anisimov A, MÀyrÀnpÀÀ MI, Lindeman JH, Eklund L, Hellberg S, Hlushchuk R, Zhuang ZW, Simons M, Djonov V, Knuuti J, Mervaala E, Alitalo K (2016) VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med 6:307-21.
|title=KivelÀ R, Bry M, Robciuc MR, RÀsÀnen M, Taavitsainen M, Silvola JM, Saraste A, Hulmi JJ, Anisimov A, MÀyrÀnpÀÀ MI, Lindeman JH, Eklund L, Hellberg S, Hlushchuk R, Zhuang ZW, Simons M, Djonov V, Knuuti J, Mervaala E, Alitalo K (2016) VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med 6:307-21.
|info=[https://www.ncbi.nlm.nih.gov/pubmed/24448490 PMID: 24448490 Open Access]
|info=[https://www.ncbi.nlm.nih.gov/pubmed/24448490 PMID: 24448490 Open Access]
|authors=Kivelae R, Bry M, Robciuc MR, Raesaenen M, Taavitsainen M, Silvola JM, Saraste A, Hulmi JJ, Anisimov A, Maeyraenpaeae MI, Lindeman JH, Eklund L, Hellberg S, Hlushchuk R, Zhuang ZW, Simons M, Djonov V, Knuuti J, Mervaala E, Alitalo K
|authors=Kivelae R, Bry M, Robciuc MR, Raesaenen M, Taavitsainen M, Silvola JM, Saraste A, Hulmi JJ, Anisimov A, Maeyraenpaeae MI, Lindeman Jan HN, Eklund L, Hellberg S, Hlushchuk R, Zhuang ZW, Simons M, Djonov V, Knuuti J, Mervaala E, Alitalo K
|year=2014
|year=2014
|journal=EMBO Mol Med
|journal=EMBO Mol Med
|abstract=Angiogenic growth factors have recently been linked to tissue metabolism. We have used genetic gain- and loss-of function models to elucidate the effects and mechanisms of action of vascular endothelial growth factor-B (VEGF-B) in the heart. A cardiomyocyte-specific VEGF-B transgene induced an expanded coronary arterial tree and reprogramming of cardiomyocyte metabolism. This was associated with protection against myocardial infarction and preservation of mitochondrial complex I function upon ischemia-reperfusion. VEGF-B increased VEGF signals via VEGF receptor-2 to activate Erk1/2, which resulted in vascular growth. Akt and mTORC1 pathways were upregulated and AMPK downregulated, readjusting cardiomyocyte metabolic pathways to favor glucose oxidation and macromolecular biosynthesis. However, contrasting with a previous theory, there was no difference in fatty acid uptake by the heart between the VEGF-B transgenic, gene-targeted or wildtype rats. Importantly, we also show that VEGF-B expression is reduced in human heart disease. Our data indicate that VEGF-B could be used to increase the coronary vasculature and to reprogram myocardial metabolism to improve cardiac function in ischemic heart disease.
|abstract=Angiogenic growth factors have recently been linked to tissue metabolism. We have used genetic gain- and loss-of function models to elucidate the effects and mechanisms of action of vascular endothelial growth factor-B (VEGF-B) in the heart. A cardiomyocyte-specific VEGF-B transgene induced an expanded coronary arterial tree and reprogramming of cardiomyocyte metabolism. This was associated with protection against myocardial infarction and preservation of mitochondrial complex I function upon ischemia-reperfusion. VEGF-B increased VEGF signals via VEGF receptor-2 to activate Erk1/2, which resulted in vascular growth. Akt and mTORC1 pathways were upregulated and AMPK downregulated, readjusting cardiomyocyte metabolic pathways to favor glucose oxidation and macromolecular biosynthesis. However, contrasting with a previous theory, there was no difference in fatty acid uptake by the heart between the VEGF-B transgenic, gene-targeted or wildtype rats. Importantly, we also show that VEGF-B expression is reduced in human heart disease. Our data indicate that VEGF-B could be used to increase the coronary vasculature and to reprogram myocardial metabolism to improve cardiac function in ischemic heart disease.
|keywords=Angiogenesis, Endothelial cell, Ischemia, Metabolism, VEGF-B
|keywords=Angiogenesis, Endothelial cell, Ischemia, Metabolism, VEGF-B
|mipnetlab=FI Helsinki Mervaala E
|mipnetlab=FI Helsinki Mervaala E, NL Leiden Lindeman JHN
}}
}}
{{Labeling
{{Labeling

Latest revision as of 12:12, 4 July 2022

Publications in the MiPMap
KivelÀ R, Bry M, Robciuc MR, RÀsÀnen M, Taavitsainen M, Silvola JM, Saraste A, Hulmi JJ, Anisimov A, MÀyrÀnpÀÀ MI, Lindeman JH, Eklund L, Hellberg S, Hlushchuk R, Zhuang ZW, Simons M, Djonov V, Knuuti J, Mervaala E, Alitalo K (2016) VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med 6:307-21.

» PMID: 24448490 Open Access

Kivelae R, Bry M, Robciuc MR, Raesaenen M, Taavitsainen M, Silvola JM, Saraste A, Hulmi JJ, Anisimov A, Maeyraenpaeae MI, Lindeman Jan HN, Eklund L, Hellberg S, Hlushchuk R, Zhuang ZW, Simons M, Djonov V, Knuuti J, Mervaala E, Alitalo K (2014) EMBO Mol Med

Abstract: Angiogenic growth factors have recently been linked to tissue metabolism. We have used genetic gain- and loss-of function models to elucidate the effects and mechanisms of action of vascular endothelial growth factor-B (VEGF-B) in the heart. A cardiomyocyte-specific VEGF-B transgene induced an expanded coronary arterial tree and reprogramming of cardiomyocyte metabolism. This was associated with protection against myocardial infarction and preservation of mitochondrial complex I function upon ischemia-reperfusion. VEGF-B increased VEGF signals via VEGF receptor-2 to activate Erk1/2, which resulted in vascular growth. Akt and mTORC1 pathways were upregulated and AMPK downregulated, readjusting cardiomyocyte metabolic pathways to favor glucose oxidation and macromolecular biosynthesis. However, contrasting with a previous theory, there was no difference in fatty acid uptake by the heart between the VEGF-B transgenic, gene-targeted or wildtype rats. Importantly, we also show that VEGF-B expression is reduced in human heart disease. Our data indicate that VEGF-B could be used to increase the coronary vasculature and to reprogram myocardial metabolism to improve cardiac function in ischemic heart disease. ‱ Keywords: Angiogenesis, Endothelial cell, Ischemia, Metabolism, VEGF-B

‱ O2k-Network Lab: FI Helsinki Mervaala E, NL Leiden Lindeman JHN


Labels: MiParea: Respiration, Pharmacology;toxicology  Pathology: Cardiovascular  Stress:Ischemia-reperfusion  Organism: Rat  Tissue;cell: Heart  Preparation: Homogenate 


Coupling state: LEAK, OXPHOS, ET  Pathway: F, N, S, NS  HRR: Oxygraph-2k